Small Cell Lung Cancer
Conditions
Keywords
Small Cell Lung Cancer, Extensive Disease, Chemotherapy, Randomisation
Brief summary
This study is a randomized, multi-center clinical trial. Patients are stratified according to performance status (ECOG 0, 1 vs 2) and institution. Patients are randomized to 1 of 2 treatment arms. Arm A: Patients receive etoposide IV on days 1, 2, 3 and cisplatin IV on day 1. Courses repeat every 3 weeks Arm B: Patients receive irinotecan IV on days 1, 8 and cisplatin IV on day 1. Coursed repeated every 3 weeks Treatment in both arms continues for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1.5 years
Interventions
DRUGIP
irinotecan+cisplatin
Sponsors
Clinical Research Center for Solid Tumor, Korea
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically diagnosed small cell lung cancer * Extensive disease (distant metastasis, contralateral hilar lymph node involvement, or cytologically confirmed malignant pleural effusion) * If patients have brain metastasis with neurological symptom, they should be stabilized neurologically with prior radiotherapy or surgery for the brain metastasis (no neurologic symptom in progress and without further steroid treatment) * No prior chemotherapy, immunotherapy, surgery or radiotherapy for small cell lung cancer (Local radiotherapy for brain or bone metastasis with symptom is permitted, in which case patients can be enrolled in this study when they have recovered from toxicity of radiotherapy) * One or more measurable disease by RECIST criteria * at least 18 years of age * Performance status of 0, 1 and 2 on the Eastern Cooperative Oncology Group (ECOG) criteria * Adequate hematologic (neutrophil count \>= 1,500/uL, platelets \>= 100,000/uL), hepatic (transaminase =\< upper normal limit(UNL)x2.5, bilirubin level =\< UNLx1.5), and renal (creatinine =\< UNL) function * Informed consent from patient which conforms to Institutional Review Board
Exclusion criteria
* History of cured basal cell carcinoma or cured uterine cervical malignancy except for carcinoma in situ within 5 years * Medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease * Uncontrolled serious infection * Enrollment in other study within 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | month |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate | percent |
| Progression free survival | month |
| Safety profile | percent |
Countries
South Korea
Outcome results
None listed